Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.
News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.
Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.
Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.
For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.
Akoustis Technologies, Inc. (NASDAQ: AKTS) will webcast its Q4FY22 results on September 12, 2022, at 8:00 am ET, followed by a Q&A session. Interested parties can join via telephone at 877-407-3982 (domestic) or 201-493-6780 (international), or watch the live webcast on the Company's website. Akoustis is ramping commercial production and plans to achieve an annual capacity of approximately 500 million units, focusing on Wi-Fi 6, Wi-Fi 6E, and 5G filter solutions. The Company has secured over 20 customer design wins for its XBAW® filter technology.
Akoustis Technologies (NASDAQ: AKTS) announced the development of two new Wi-Fi 7 diplexers utilizing XBAW RF filters after receiving an order from a Fortune 100 Internet company. Pre-production is slated for the second half of 2023, with full production expected in early 2024. The diplexers target applications in AR/VR and wearables, marking a significant step in Akoustis’ product expansion. The company aims for an annual production capacity of 500 million units, building on over 20 customer design wins for its XBAW solutions.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced its participation in the 3rd Annual Needham Semiconductor and SemiCap Conference from August 24-25, 2022. Senior management will hold one-on-one meetings on August 24 for interested investors. The company is ramping production capacity to 500 million units annually and has achieved over 20 design wins for its XBAW® filter solutions, including Wi-Fi 6 and 5G small cell filters. Akoustis aims to capture the growing RF filter market with its advanced manufacturing techniques and a dedicated facility in Canandaigua, NY.
Akoustis Technologies announced that CEO Jeff Shealy will discuss the CHIPS and Science Act 2022 on Cavuto: Coast to Coast at 1:20 PM ET. Key topics include the global chip shortage, 5G network rollouts, and the company’s XBAW® filter products. Akoustis is producing Wi-Fi 6 tandem filters and has secured over 20 customer design wins for its XBAW® filters, highlighting ongoing growth and market engagement. The company operates a manufacturing facility in New York, supporting its expansion in the RF filter market.
Akoustis Technologies (NASDAQ: AKTS) announced progress in its 5G mobile filter development, unveiling the second design iteration of its XBAW® filter, recently shipped to a foundry customer. The new filter targets mobile applications and is expected to ramp production in late 2023. The company has achieved over 20 design wins for its XBAW® solutions and is advancing its wafer-level packaging technology at its New York facility. CEO Jeff Shealy highlighted mobile sector growth as a significant opportunity for Akoustis, with expectations for substantial market penetration in the coming years.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced that CEO Jeff Shealy will appear on Yahoo Finance to discuss significant topics including the CHIPS and Science Act 2022, global chip shortages, and the company's made-in-America XBAW® filters. The company has achieved over 20 customer design wins for its patented filters and is in active production of various Wi-Fi 6 and 5G solutions. Akoustis aims to capture a share of the growing RF filter market from its state-of-the-art facility in New York, addressing demands for enhanced performance in mobile and wireless applications.
Akoustis Technologies, Inc. (NASDAQ: AKTS) has appointed Kamran Cheema as the new Chief Product Officer, effective immediately. Cheema, who joined the company in August 2021 as VP of Engineering, has over 30 years of experience in RF technology. He will oversee product design and device engineering, focusing on the development of acoustic RF filter products for markets such as 5G mobile and Wi-Fi. Akoustis is actively manufacturing Wi-Fi 6 tandem solutions and has secured over 20 customer design wins for its XBAW® filter technology.
Akoustis Technologies, Inc. (NASDAQ: AKTS) has secured a multi-year, multi-million dollar contract from the Defense Advanced Research Projects Agency (DARPA) to enhance its patented XBAW technology for high-band RF filters. This initiative aims to extend operational capability to 18 GHz, targeting both commercial and defense markets. The company's CEO, Jeff Shealy, highlighted advancements in BAW resonator technology to maintain high quality factors at elevated frequencies. Additionally, Akoustis is scaling its NY fabrication facility to support increased production for burgeoning 5G and Wi-Fi markets.
Akoustis Technologies, Inc. (NASDAQ: AKTS) will exhibit at the IEEE MTT International Microwave Symposium 2022 in Denver from June 21-23. Dr. Rama Vetury will present on miniaturized Wi-Fi 6E diplexer technology. Akoustis will showcase products including RF BAW filters and SAW filters, targeting the rapidly growing demand for Wi-Fi 6 and 5G solutions. The company is ramping up production capacity to 500 million filters annually in response to increasing customer engagements and design wins, exceeding 20 to date.
Akoustis Technologies (NASDAQ: AKTS) announced the ramp-up of production for its XBAW filters used in Aruba's new Wi-Fi 6E Access Points, the AP-635 and AP-655. These Access Points are the first to support full Wi-Fi 6E and 5 GHz spectrum simultaneously, enhancing technology leadership in the industry. With multiple custom filters integrated, they achieve optimal performance across tri-band coverage. Akoustis plans to increase its production capacity to 500 million filters annually, responding to a growing demand for 5G and Wi-Fi solutions.